SA520411112B1 - عملية محسّنة لتحضير مشتقات أمينو بيريميدين - Google Patents
عملية محسّنة لتحضير مشتقات أمينو بيريميدينInfo
- Publication number
- SA520411112B1 SA520411112B1 SA520411112A SA520411112A SA520411112B1 SA 520411112 B1 SA520411112 B1 SA 520411112B1 SA 520411112 A SA520411112 A SA 520411112A SA 520411112 A SA520411112 A SA 520411112A SA 520411112 B1 SA520411112 B1 SA 520411112B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- preparing
- improved process
- aminopyrimidine derivatives
- protein kinases
- present
- Prior art date
Links
- 150000005005 aminopyrimidines Chemical class 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108060006633 protein kinase Proteins 0.000 abstract 2
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 108060006698 EGF receptor Proteins 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/22—Tin compounds
- C07F7/2284—Compounds with one or more Sn-N linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Catalysts (AREA)
Abstract
يوفر الاختراع الحالي عملية محسّنة لتحضير مشتقات أمينو بيريميدين أو أملاح منه مقبولة صيدلانيًا تتميز بنشاط تثبيطي انتقائي ضد كينازات البروتين، وخاصة ضد كينازات البروتين لمستقبلات عوامل النمو البشروية الطافرة. ويوفر الاختراع الحالي أيضًا مركبات وسيطة جديدة مفيدة للعملية المذكورة ولعمليات من أجل تحضيرها.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170096212 | 2017-07-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA520411112B1 true SA520411112B1 (ar) | 2022-02-21 |
Family
ID=65040211
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA522431428A SA522431428B1 (ar) | 2017-07-28 | 2020-01-21 | عملية محسّنة لتحضير مشتقات أمينو بيريميدين |
| SA520411112A SA520411112B1 (ar) | 2017-07-28 | 2020-01-21 | عملية محسّنة لتحضير مشتقات أمينو بيريميدين |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA522431428A SA522431428B1 (ar) | 2017-07-28 | 2020-01-21 | عملية محسّنة لتحضير مشتقات أمينو بيريميدين |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US10889578B2 (ar) |
| EP (1) | EP3658552B1 (ar) |
| JP (2) | JP7228562B2 (ar) |
| KR (1) | KR102688084B1 (ar) |
| CN (2) | CN116987112B (ar) |
| AU (2) | AU2018308038B2 (ar) |
| BR (1) | BR112020001278A2 (ar) |
| CA (1) | CA3070069C (ar) |
| CO (1) | CO2020000374A2 (ar) |
| DK (1) | DK3658552T3 (ar) |
| EA (1) | EA202090383A1 (ar) |
| ES (1) | ES2962961T3 (ar) |
| FI (1) | FI3658552T3 (ar) |
| HR (1) | HRP20231191T1 (ar) |
| HU (1) | HUE063533T2 (ar) |
| IL (2) | IL271973B (ar) |
| LT (1) | LT3658552T (ar) |
| MA (1) | MA49700B1 (ar) |
| MD (1) | MD3658552T2 (ar) |
| MX (2) | MX393995B (ar) |
| MY (1) | MY198379A (ar) |
| PH (1) | PH12020500059A1 (ar) |
| PL (1) | PL3658552T3 (ar) |
| PT (1) | PT3658552T (ar) |
| RS (1) | RS64654B1 (ar) |
| SA (2) | SA522431428B1 (ar) |
| SG (1) | SG11201913517UA (ar) |
| SI (1) | SI3658552T1 (ar) |
| SM (1) | SMT202300339T1 (ar) |
| UA (1) | UA125317C2 (ar) |
| WO (1) | WO2019022485A1 (ar) |
| ZA (1) | ZA202001250B (ar) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2962961T3 (es) | 2017-07-28 | 2024-03-22 | Yuhan Corp | Procedimiento de preparación de n-(5-((4-(4-(dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamida haciendo reaccionar la amina correspondiente con un cloruro de 3-halo-propionilo |
| MY208668A (en) | 2019-05-14 | 2025-05-23 | Janssen Biotech Inc | Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| BR112022015140A2 (pt) | 2020-02-12 | 2022-10-11 | Janssen Biotech Inc | Tratamento de pacientes que têm mutações de salto do éxon 14 de c-met |
| TWI923583B (zh) | 2020-04-14 | 2026-05-01 | 美商健生生物科技公司 | 包含胺基嘧啶衍生物或其醫藥上可接受之鹽之用於經口投予之醫藥組成物 |
| US11780824B2 (en) * | 2020-12-16 | 2023-10-10 | Scinopharm Taiwan, Ltd. | Process for preparing osimertinib or a salt thereof |
| CN116199701A (zh) * | 2023-02-27 | 2023-06-02 | 安徽中医药大学 | 一种基于分子内自由基环加成制备吡唑并恶嗪草酮类化合物及其制备方法 |
| CA3228195A1 (en) | 2023-05-23 | 2025-06-30 | Janssen Biotech, Inc. | Methods for treatment of non-small cell lung cancer (nsclc) |
| IL326946A (en) | 2023-09-05 | 2026-05-01 | Janssen Biotech Inc | Methods of treating non-small cell lung cancer |
| WO2026042017A1 (en) | 2024-08-19 | 2026-02-26 | Janssen Biotech, Inc. | Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc) |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| US6821988B2 (en) | 2001-11-27 | 2004-11-23 | Wyeth Holdings Corporation | 3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| RU2007123675A (ru) | 2004-11-24 | 2008-12-27 | Новартис АГ (CH) | Комбинации ингибиторов jak |
| US20060270600A1 (en) | 2005-05-26 | 2006-11-30 | Eisuke Mekada | Anti-cancer agents |
| TW200736232A (en) | 2006-01-26 | 2007-10-01 | Astrazeneca Ab | Pyrimidine derivatives |
| MX2009004426A (es) | 2006-10-23 | 2009-08-12 | Cephalon Inc | Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met. |
| TW200840581A (en) | 2007-02-28 | 2008-10-16 | Astrazeneca Ab | Novel pyrimidine derivatives |
| WO2008124085A2 (en) | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
| AU2009262068C1 (en) | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| KR20120114224A (ko) | 2009-10-12 | 2012-10-16 | 마이렉시스 인코포레이티드 | Ｉｋｋ 엡실론 및/또는 ｔｂｋ１의 억제제로서의 아미노-피리미딘 화합물 |
| CA2780892C (en) * | 2009-11-13 | 2017-02-14 | Genosco | Kinase inhibitors |
| PL2509602T3 (pl) | 2009-12-04 | 2017-08-31 | Senhwa Biosciences, Inc. | Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2 |
| KR101594002B1 (ko) | 2010-10-06 | 2016-02-15 | 글락소스미스클라인 엘엘씨 | Ｐｉ３ 키나제 억제제로서의 벤즈이미다졸 유도체 |
| JP5956999B2 (ja) | 2010-11-01 | 2016-07-27 | セルジーン アヴィロミクス リサーチ， インコーポレイテッド | ヘテロアリール化合物およびその使用 |
| UY33801A (es) | 2010-12-13 | 2013-06-28 | Array Biopharma Inc | COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III |
| DK3686193T3 (da) | 2011-07-27 | 2022-05-30 | Astrazeneca Ab | 2-(2,4,5-substitueret anilino)pyrimidinforbindelser |
| TW201331194A (zh) | 2011-12-23 | 2013-08-01 | Millennium Pharm Inc | 雜芳基化合物及其用途 |
| SG11201402765TA (en) | 2011-12-30 | 2014-06-27 | Hanmi Pharm Ind Co Ltd | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES |
| CN104860891B (zh) | 2014-02-25 | 2017-06-30 | 上海海雁医药科技有限公司 | 芳氨基嘧啶类化合物及其应用以及由其制备的药物组合物和药用组合物 |
| US20170166598A1 (en) | 2014-05-13 | 2017-06-15 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| CN111875585B (zh) | 2014-06-12 | 2023-06-23 | 上海艾力斯医药科技股份有限公司 | 一类激酶抑制剂 |
| EP3929190B1 (en) * | 2014-10-13 | 2024-12-25 | Yuhan Corporation | Compounds and compositions for modulating egfr mutant kinase activities |
| CN104788427B (zh) * | 2015-02-05 | 2017-05-31 | 上海泓博智源医药股份有限公司 | 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用 |
| AR102263A1 (es) | 2015-10-14 | 2017-02-15 | Yuhan Corp | Compuestos y composiciones para la modulación de las actividades quinasa del receptor de egf mutante |
| AR111469A1 (es) | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| DE102017212159A1 (de) | 2017-07-14 | 2019-01-17 | Krones Aktiengesellschaft | Verfahren und Vorrichtung zur Handhabung von Stückgütern, Artikeln und/oder Gebinden |
| DK3658547T3 (da) | 2017-07-28 | 2023-10-16 | Yuhan Corp | Fremgangsmåde til fremstilling af n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamid |
| RS63497B1 (sr) | 2017-07-28 | 2022-09-30 | Yuhan Corp | Intermedijeri korisni za sintezu derivata aminopirimidina, proces za pripremu istih i proces za pripremu derivata aminopirimidina korišćenjem istih |
| ES2962961T3 (es) | 2017-07-28 | 2024-03-22 | Yuhan Corp | Procedimiento de preparación de n-(5-((4-(4-(dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamida haciendo reaccionar la amina correspondiente con un cloruro de 3-halo-propionilo |
| CN108826170A (zh) | 2018-06-26 | 2018-11-16 | 深圳市远润欣电子有限公司 | 局部全般照明的模式、控制方法及台灯 |
-
2018
- 2018-07-25 ES ES18837360T patent/ES2962961T3/es active Active
- 2018-07-25 MY MYPI2020000438A patent/MY198379A/en unknown
- 2018-07-25 WO PCT/KR2018/008379 patent/WO2019022485A1/en not_active Ceased
- 2018-07-25 EA EA202090383A patent/EA202090383A1/ru unknown
- 2018-07-25 UA UAA202001303A patent/UA125317C2/uk unknown
- 2018-07-25 JP JP2020504203A patent/JP7228562B2/ja active Active
- 2018-07-25 MD MDE20200593T patent/MD3658552T2/ro unknown
- 2018-07-25 HU HUE18837360A patent/HUE063533T2/hu unknown
- 2018-07-25 PL PL18837360.9T patent/PL3658552T3/pl unknown
- 2018-07-25 SI SI201830998T patent/SI3658552T1/sl unknown
- 2018-07-25 CA CA3070069A patent/CA3070069C/en active Active
- 2018-07-25 KR KR1020180086376A patent/KR102688084B1/ko active Active
- 2018-07-25 CN CN202310702453.8A patent/CN116987112B/zh active Active
- 2018-07-25 AU AU2018308038A patent/AU2018308038B2/en active Active
- 2018-07-25 EP EP18837360.9A patent/EP3658552B1/en active Active
- 2018-07-25 MX MX2020001041A patent/MX393995B/es unknown
- 2018-07-25 PT PT188373609T patent/PT3658552T/pt unknown
- 2018-07-25 HR HRP20231191TT patent/HRP20231191T1/hr unknown
- 2018-07-25 RS RS20230834A patent/RS64654B1/sr unknown
- 2018-07-25 CN CN201880048638.9A patent/CN111315742B/zh active Active
- 2018-07-25 SM SM20230339T patent/SMT202300339T1/it unknown
- 2018-07-25 IL IL271973A patent/IL271973B/en unknown
- 2018-07-25 SG SG11201913517UA patent/SG11201913517UA/en unknown
- 2018-07-25 MA MA49700A patent/MA49700B1/fr unknown
- 2018-07-25 MX MX2022008743A patent/MX2022008743A/es unknown
- 2018-07-25 BR BR112020001278-5A patent/BR112020001278A2/pt unknown
- 2018-07-25 FI FIEP18837360.9T patent/FI3658552T3/fi active
- 2018-07-25 LT LTEPPCT/KR2018/008379T patent/LT3658552T/lt unknown
- 2018-07-25 DK DK18837360.9T patent/DK3658552T3/da active
- 2018-07-25 US US16/633,684 patent/US10889578B2/en active Active
-
2020
- 2020-01-07 PH PH12020500059A patent/PH12020500059A1/en unknown
- 2020-01-15 CO CONC2020/0000374A patent/CO2020000374A2/es unknown
- 2020-01-21 SA SA522431428A patent/SA522431428B1/ar unknown
- 2020-01-21 SA SA520411112A patent/SA520411112B1/ar unknown
- 2020-02-27 ZA ZA2020/01250A patent/ZA202001250B/en unknown
- 2020-12-08 US US17/115,037 patent/US11286253B2/en active Active
-
2022
- 2022-03-25 US US17/704,718 patent/US11708362B2/en active Active
- 2022-04-24 IL IL292429A patent/IL292429B2/en unknown
- 2022-05-03 AU AU2022202936A patent/AU2022202936B2/en active Active
- 2022-11-18 JP JP2022184867A patent/JP7539451B2/ja active Active
-
2023
- 2023-06-02 US US18/328,267 patent/US12187714B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500059A1 (en) | Improved process for preparing aminopyrimidine derivatives | |
| SA520411120B1 (ar) | مركبات وسيطة مبتكرة مفيدة لتركيب مشتقات الأمينوبيريميدين، وعملية لتحضير هذه المركبات الوسيطة، وعملية لتحضير مشتقات الأمينوبيريميدين باستخدام هذه المركبات | |
| PH12020500093A1 (en) | Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same | |
| ZA202202097B (en) | Amino pyrimidine ssao inhibitors | |
| AU2018271990A1 (en) | Covalent inhibitors of KRAS | |
| MX393879B (es) | Métodos de preparación de niraparib. | |
| PH12017550004A1 (en) | Heterocyclic derivatives and use thereof | |
| CA2983481A1 (en) | Janus kinase inhibitor | |
| SG11201906435SA (en) | Pyrimidine compound and pharmaceutical use thereof | |
| MX2019005504A (es) | Potenciadores de bmp. | |
| AU2018375456A1 (en) | Thieno(3,2-d)pyrimidine compound having inhibitory activity for protein kinase | |
| MY202856A (en) | Hardness-adjustable mattress assembly | |
| AU2019248350A8 (en) | Process for making sarecycline hydrochloride | |
| WO2018193415A9 (en) | Process for the preparation of pirlindole enantiomers and its salts | |
| HK40013334A (en) | Processes for preparing ag-10, its intermediates, and salts thereof | |
| UA123593U (uk) | 2-(7-ФУРАН-21-ІЛ-2-МОРФОЛІН-41-ІЛ-4-ОКСО-4Н-ТІАЗОЛО[4,5-d]ПІРИДАЗИН-5-ІЛ)-N-НАФТАЛІН-1-ІЛАЦЕТАМІД, ЩО МАЄ ПРОТИПУХЛИННУ АКТИВНІСТЬ |